Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by Lexaria Bioscience Corp. Lexaria Bioscience Corp. (NASDAQ: LEXX) Proprietary Drug-Delivery System Improves Way Molecules Enter Bloodstream January 11, 2024 From Lexaria Bioscience Corp. Via GlobeNewswire Tickers LEXX Lexaria Bioscience Corp. (NASDAQ: LEXX) Improves Delivery, Efficacy of GLP-1 Agonists Through Proprietary Drug-Delivery Platform January 09, 2024 From Lexaria Bioscience Corp. Via GlobeNewswire Tickers LEXX Lexaria Bioscience Corp. (NASDAQ: LEXX) Expands Studies of Proprietary Platform in Multibillion-Dollar GLP-1 Drug Space November 01, 2023 From Lexaria Bioscience Corp. Via GlobeNewswire Tickers LEXX Lexaria Bioscience Corp. (NASDAQ: LEXX) Evaluating Proprietary Drug-Delivery Platform for Improved Efficacy of GLP-1 Drugs October 31, 2023 From Lexaria Bioscience Corp. Via GlobeNewswire Tickers LEXX Lexaria's DehydraTECH-CBD Hypertension Study HYPER-H21-4 Dosing Complete with No Serious Adverse Events July 27, 2022 From Lexaria Bioscience Corp. Via AccessWire Exposures Product Safety Tickers LEXX LEXXW Lexaria's Licensee Premier Wellness Science Co., Ltd. Launches New Brand in Preparation to Deploy DehydraTECH CBD Products in Japan July 26, 2022 From Lexaria Bioscience Corp. Via AccessWire Topics Supply Chain Exposures Supply Chain Tickers LEXX LEXXW Lexaria To Receive Third Patent Granted in Japan; Submits FDA Filing July 14, 2022 From Lexaria Bioscience Corp. Via AccessWire Topics Intellectual Property Exposures Intellectual Property Product Safety Tickers LEXX LEXXW Lexaria's Human Nicotine Study Nearing Start Date July 13, 2022 From Lexaria Bioscience Corp. Via AccessWire Topics Intellectual Property Exposures Intellectual Property Tickers LEXX LEXXW Cannadips is Expanding Internationally, Leveraging Lexaria's DehydraTECH July 07, 2022 From Lexaria Bioscience Corp. Via AccessWire Tickers LEXX LEXXW Lexaria Signs Manufacturing and License Agreements with BevNology June 21, 2022 From Lexaria Bioscience Corp. Via AccessWire Tickers LEXX LEXXW Lexaria Grants License to AnodGen Bioceuticals June 08, 2022 From Lexaria Bioscience Corp. Via AccessWire Tickers LEXX LEXXW Lexaria Files Pre-IND Meeting Request Letter with U.S. FDA June 06, 2022 From Lexaria Bioscience Corp. Via AccessWire Exposures Product Safety Tickers LEXX LEXXW Lexaria Grants Exclusive License to Premier Wellness Science Co., Ltd. for Strategic and Long-Term Partnership in the Japanese Market June 03, 2022 From Lexaria Bioscience Corp. Via AccessWire Tickers LEXX LEXXW Lexaria Grants License to Valcon Medical for the European Market June 02, 2022 From Lexaria Bioscience Corp. Via AccessWire Topics Cannabis Exposures Cannabis Tickers LEXX LEXXW Lexaria Announces 2022 Annual Meeting Results June 01, 2022 From Lexaria Bioscience Corp. Via AccessWire Tickers LEXX LEXXW Lexaria Granted Patent for Use of DehydraTECH to Deliver Antiviral Drugs April 21, 2022 From Lexaria Bioscience Corp. Via AccessWire Topics Intellectual Property Exposures Intellectual Property Tickers LEXX LEXXW Lexaria Commences Multi-Week Human Clinical Hypertension Study April 19, 2022 From Lexaria Bioscience Corp. Via AccessWire Tickers LEXX LEXXW Lexaria's Pulmonary Hypertension Clinical Study HYPER-H21-3 Delivers Positive Results April 14, 2022 From Lexaria Bioscience Corp. Via AccessWire Tickers LEXX LEXXW Lexaria Provides Update on Human Nicotine Study NIC-H22-1 April 12, 2022 From Lexaria Bioscience Corp. Via AccessWire Tickers LEXX LEXXW Lexaria Begins New Nicotine Formulation Creation and Evaluation Program April 11, 2022 From Lexaria Bioscience Corp. Via AccessWire Tickers LEXX LEXXW Lexaria Begins DehydraTECH-CBD Epilepsy Research Program March 15, 2022 From Lexaria Bioscience Corp. Via AccessWire Tickers LEXX LEXXW Lexaria Granted Important New Oral Nicotine Patent March 08, 2022 From Lexaria Bioscience Corp. Via AccessWire Topics Intellectual Property Exposures Intellectual Property Tickers LEXX LEXXW Lexaria Reports Potentially Ground-Breaking Findings in Sildenafil Animal Study February 02, 2022 From Lexaria Bioscience Corp. Via AccessWire Tickers LEXX LEXXW Lexaria Provides Annual Letter From the CEO January 27, 2022 From Lexaria Bioscience Corp. Via AccessWire Tickers LEXX LEXXW Lexaria Comments on Study Examining Cannabinoids and SARS-CoV-2 January 18, 2022 From Lexaria Bioscience Corp. Via AccessWire Tickers LEXX LEXXW Lexaria Receives Independent Review Board Approval For DehydraTECH-CBD Human Clinical Study HYPER-H21-4 December 29, 2021 From Lexaria Bioscience Corp. Via AccessWire Tickers LEXX LEXXW Lexaria Enters One-Year Media Outreach Agreement with SRAX, Inc. December 16, 2021 From Lexaria Bioscience Corp. Via AccessWire Tickers LEXX LEXXW Lexaria's Clinical Hypertension Study HYPER-H21-3 Nears Completion December 14, 2021 From Lexaria Bioscience Corp. Via AccessWire Tickers LEXX LEXXW Lexaria's DehydraTECHTM-CBD Reduces Arterial Stiffness, Results Confirmed in Human Clinical Study HYPER-H21-2 December 08, 2021 From Lexaria Bioscience Corp. Via AccessWire Topics Intellectual Property Exposures Intellectual Property Tickers LEXX LEXXW Lexaria 2022 R&D Programs to Include Investigations into Alzheimer's Disease and Diabetes November 10, 2021 From Lexaria Bioscience Corp. Via AccessWire Topics Death Intellectual Property Exposures Death Intellectual Property Tickers LEXX LEXXW Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.